Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Tempus AI — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.56 (market cap $16.72B), while Tempus AI trades at $70.2 (market cap $12.58B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Tempus AI is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Tempus AI for 22 Days on average.
| IEI | TEM | |
|---|---|---|
Market Cap | $16.72B | $12.58B |
Volume | 3,963,319 | 7,444,569 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $120.72 | $99.28 |
52-Week Low | $113.17 | $41.55 |
Typical Hold Time | 43 Days | 22 Days |
Enterprise Value | — | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.38 with minimal daily movement (+0.04%). The technical picture shows strong bearish momentum across moving averages and oscillators, with key indicators like the ADX signaling strong downward trends. Recent bond market volatility and rising Treasury yields create a challenging environment for fixed-income related investments. The company has maintained consistent dividend payments, with recent distributions of $0.37-$0.38 per share.
The outlook remains cautious given the bearish technical signals and broader bond market pressures. While dividend consistency provides some stability, the lack of available fundamental metrics and negative technical momentum suggests limited near-term upside potential. Investors should monitor Treasury yield developments and company financial disclosures for clearer directional signals.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
